RecruitingNot applicableEN originalColorectal cancer

ULTRA-high-risk Surveillance to Avoid Future Events: the ULTRA-SAFE Trial

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The ULTRA-SAFE clinical trial is a prospective, randomized study designed to address the limitations of current "one-size-fits-all" colorectal cancer surveillance guidelines. While international standards recommend a three-year follow-up colonoscopy for all high-risk patients, data suggests that those with multiple advanced adenomas face a significantly higher recurrence risk (20%) compared to those with only low-risk adenomas (9%). To provide more personalized care, the trial compares a Standard Arm (colonoscopy at year three) against a FIT Arm, where participants undergo annual fecal immunochemical testing in years one and two. A positive FIT triggers an earlier colonoscopy, with the goal of reducing the 3-year prevalence of metachronous advanced colorectal neoplasms (meta-ACRN) from 20% to approximately 12.7%. The study has enrolled roughly 940 participants to statistically validate whether this early screening intervention can effectively prevent future malignant events in ultra-high-risk populations.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek 40-75 lat
  • Stwierdzenie i usunięcie co najmniej dwóch poważnych polipaków podczas pierwszej kolonoskopii
  • Gotowość do uczestnictwa w badaniu i wykonywania badań zgodnie z planem

✗ Disqualifies

  • Wiek poniżej 40 lub powyżej 75 lat
  • Choroba zapalna jelit (IBD), rodzinna polipoza grubego jelita (FAP) lub dziedziczne zespoły raka
  • Historia raka jelita grubego
  • Bezpieczeństwo zdrowotne pacjenta - sytuacje, w których usuwanie polipaków nie jest bezpieczne
  • Brak co najmniej dwóch poważnych polipaków podczas pierwszej kolonoskopii
  • Więcej niż 10 łagodnych polipaków
  • Ciąża

Simplified criteria — AI translation

Trial details

Minimum age
40 Years
Maximum age
75 Years
Last updated (source)
August 26, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (4)

National Taiwan University Hospital

Taipei, Taiwan

National Taiwan University Hospital Hsinchu Branch

Hsinchu, Taiwan

Fu Jen Catholic University Hospital

New Taipei City, Taiwan

National Taiwan University Cancer Center

Taipei, Taiwan

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/27/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.